ANGOAngiodynamic Inc
$11.94
$0.09
(0.75%)
Closed $11.94
$0.00
(0.00%)
After Hours
EarningsJul 15
Mkt Cap$497.07M
Vol385,235.00
Fundamentals
Mkt Cap
$497.07M
Volume
-
52W High
$13.99
52W Low
$8.36
PE Ratio
-15.84
Avg. Volume
295,441.75
EPS (Annual)
-$0.8321
Rev/Employee
$433,330.37
Earnings
Jul 15
Thermo Fisher (TMO) Surges 6.8%: Is This an Indication of Further Gains?
Thermo Fisher (TMO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Zacks
AngioDynamics Expands Patient Access to NanoKnife IRE for Prostate and Liver Cancer as Medicare Coverage Framework Takes Effect
AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that Palmetto GBA has issued a final Local Coverage Determination (LCD...
Business Wire
AngioDynamics to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the bodys vascular system, expanding cancer treatment options and improving patient quality of life, today announced that the management team will present at the...
Business Wire
Wall Street Analysts See a 50.5% Upside in AngioDynamics (ANGO): Can the Stock Really Move This High?
The mean of analysts' price targets for AngioDynamics (ANGO) points to a 50.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks
Reasons to Add AngioDynamics Stock to Your Portfolio for Now
ANGO gains momentum as NanoKnife adoption, strong Med Tech growth and positive clinical trends support its long-term outlook.
Zacks
AngioDynamics Announces Two-Year PRESERVE Trial Data Demonstrating Durable NanoKnife IRE System Outcomes in Intermediate-Risk Prostate Cancer
AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient...
Business Wire
Wall Street Analysts Think AngioDynamics (ANGO) Could Surge 64.23%: Read This Before Placing a Bet
The mean of analysts' price targets for AngioDynamics (ANGO) points to a 64.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks
136,333 Shares in AngioDynamics, Inc. $ANGO Bought by D.A. Davidson & CO.
D.A. Davidson & CO. acquired a new position in shares of AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange...
MarketBeat
AngioDynamics, Inc. (NASDAQ:ANGO) Short Interest Up 18.7% in April
AngioDynamics, Inc. (NASDAQ:ANGO - Get Free Report) was the recipient of a large increase in short interest during the month of April. As of April 15th, there was short interest totaling 2,161,213...
MarketBeat
Weber Capital Management LLC ADV Invests $17.98 Million in AngioDynamics, Inc. $ANGO
Weber Capital Management LLC ADV acquired a new position in AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 1,400,149 shares of the medical instruments su...
MarketBeat
<
1
2
...
>
Advertisement|Remove ads.
Latest ANGO News
ViewThermo Fisher (TMO) Surges 6.8%: Is This an Indication of Further Gains?
Zacks
AngioDynamics Expands Patient Access to NanoKnife IRE for Prostate and Liver Cancer as Medicare Coverage Framework Takes Effect
Business Wire
AngioDynamics to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Business Wire
Advertisement|Remove ads.